Salman Abbasi Fard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Salman Abbasi Fard has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Payam Moein
Department of Neurosurgery, Al-Zahra Hospital, Isfahan University Of Medical Sciences, Isfahan, Iran
2 shared publications- Ahmad Shekarchizadeh
Department of Neurosurgery, Kashani Hospital, Isfahan University Of Medical Sciences, Isfahan, Iran
1 shared publication Bahram Aminmansour
Department of Neurosurgery, Al-Zahra Hospital, Isfahan University Of Medical Sciences, Isfahan, Iran
1 shared publication- Homayoun Tabesh
Department of Neurosurgery School of Medicine, Isfahan University of Medical Sciences Isfahan Iran
1 shared publication Hooshang Md Moein
Department of Neurosurgery, Al-Zahra Hospital
1 shared publicationMajidRezvani Habibabadi
Department of Neurosurgery, Al-Zahra Hospital, Isfahan University Of Medical Sciences, Isfahan, Iran
1 shared publication
Latest Publications
- Open Access
- 1 January 2014
- Published by Medknow in Advanced Biomedical Research
- Vol. 3 (1) , 35
The efficacy of cyclosporine-A on diffuse axonal injury after traumatic brain injury
Background: To evaluate the efficacy and side-effects of cyclosporine-A (CsA) in improvement of consciousness and cognitive dysfunction of patients with diffuse axonal injury (DAI) after traumatic brain injury (TBI). Materials and Methods: This study is designed as a randomized double-blind placebo-controlled with 100 patients suffered from DAI. CsA was administered to the intervention group (n = 50) as 5 mg/kg/24 h via 250 ml dextrose water (DW) 5% solution (DW 5%) during the first 8 h after trauma. The control group (n = 50) received only DW 5% in the same course. The presenting Glasgow coma scale in addition to the Glasgow outcome scale-extended (GOS-E) and mini-mental state examination (MMSE) in the 3 rd and 6 th months after trauma were documented. The serum values for complete blood count (CBC), blood urea nitrogen (BUN), creatinine (Cr), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) were checked to assess for complications. Results: Most patients in both groups had type II DAI (46%). There was no significant difference between groups in the GOS-E scores after 3 and 6 months. All participants were in moderate or severe classes of MMSE with no statistically significant difference. Except for the higher BUN level in the cyclosporine treated group, 48 h after admission (P = 0.012), the difference in the level of Cr, AST, ALT, and ALP was not significant and all were in the normal range. The CBC results showed only significant difference for White Blood Cell (WBC) count at 12 h (P = 0.000). Conclusion: The administration of CsA is not effective in the improvement of consciousness and cognitive function. However, it brings about no adverse effects.
- 1 January 2014
- Published by Medknow in Advanced Biomedical Research
- Vol. 3 (1) , 35
Open AccessThe efficacy of cyclosporine-A on diffuse axonal injury after traumatic brain injury
Background: To evaluate the efficacy and side-effects of cyclosporine-A (CsA) in improvement of consciousness and cognitive dysfunction of patients with diffuse axonal injury (DAI) after traumatic brain injury (TBI). Materials and Methods: This study is designed as a randomized double-blind placebo-controlled with 100 patients suffered from DAI. CsA was administered to the intervention group (n = 50) as 5 mg/kg/24 h via 250 ml dextrose water (DW) 5% solution (DW 5%) during the first 8 h after trauma. The control group (n = 50) received only DW 5% in the same course. The presenting Glasgow coma scale in addition to the Glasgow outcome scale-extended (GOS-E) and mini-mental state examination (MMSE) in the 3 rd and 6 th months after trauma were documented. The serum values for complete blood count (CBC), blood urea nitrogen (BUN), creatinine (Cr), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) were checked to assess for complications. Results: Most patients in both groups had type II DAI (46%). There was no significant difference between groups in the GOS-E scores after 3 and 6 months. All participants were in moderate or severe classes of MMSE with no statistically significant difference. Except for the higher BUN level in the cyclosporine treated group, 48 h after admission (P = 0.012), the difference in the level of Cr, AST, ALT, and ALP was not significant and all were in the normal range. The CBC results showed only significant difference for White Blood Cell (WBC) count at 12 h (P = 0.000). Conclusion: The administration of CsA is not effective in the improvement of consciousness and cognitive function. However, it brings about no adverse effects.
- 1 August 2012
- Published by Wolters Kluwer Health in Neurosurgery Quarterly
- Vol. 22 (3) , 149-152
Outcome of Decompressive Craniectomy in Patients With Severe Head Injury
Background: Head injury is the most important cause of death caused by trauma. Decompressive craniectomy is the best-known way to reduce otherwise intractable intracranial pressure and its complications in traumatic brain injury. Aim: This aim of this study was to evaluate the outcome of patients with decompressive craniectomy after severe traumatic brain injury and compare with a control group. Setting: Al-Zahra and Kashani hospital in Isfahan. Design: Pilot randomized clinical trial. Methods: Twenty patients were entered in this study. Patients were randomly divided into group A and group B. Group A received surgical and conservative treatment and group B underwent conservative treatment alone. Both groups were then followed for 6 months. Both groups’ presentation Glasgow Coma Scale and Glasgow Outcome Scale (GOS) were compared. Results: A favorable GOS was achieved in 6 cases (60%) of patients in group A and in 2 cases (20%) in group B. However, the difference was not statistically significant. The death rate was higher in group B, with 3 cases (30%), and only 1 patient (10%) died in group A, but the difference was not significant. Conclusions: Decompressive craniectomy seems to be helpful and may lead to a better GOS achievement and improve the mortality rate among traumatic brain injury patients; however, further investigation will be needed to confirm the results.
- 1 August 2012
- Published by Wolters Kluwer Health in Neurosurgery Quarterly
- Vol. 22 (3) , 149-152
Outcome of Decompressive Craniectomy in Patients With Severe Head Injury
Background: Head injury is the most important cause of death caused by trauma. Decompressive craniectomy is the best-known way to reduce otherwise intractable intracranial pressure and its complications in traumatic brain injury. Aim: This aim of this study was to evaluate the outcome of patients with decompressive craniectomy after severe traumatic brain injury and compare with a control group. Setting: Al-Zahra and Kashani hospital in Isfahan. Design: Pilot randomized clinical trial. Methods: Twenty patients were entered in this study. Patients were randomly divided into group A and group B. Group A received surgical and conservative treatment and group B underwent conservative treatment alone. Both groups were then followed for 6 months. Both groups’ presentation Glasgow Coma Scale and Glasgow Outcome Scale (GOS) were compared. Results: A favorable GOS was achieved in 6 cases (60%) of patients in group A and in 2 cases (20%) in group B. However, the difference was not statistically significant. The death rate was higher in group B, with 3 cases (30%), and only 1 patient (10%) died in group A, but the difference was not significant. Conclusions: Decompressive craniectomy seems to be helpful and may lead to a better GOS achievement and improve the mortality rate among traumatic brain injury patients; however, further investigation will be needed to confirm the results.
- Open Access
- 19 December 2011
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 5 (1) , 580
An intracranial extramedullary hematopoiesis in a 34-year-old man with beta thalassemia: a case report
Introduction: Extramedullary hematopoiesis occurs in approximately 15% of cases of thalassemia. Intracranial deposits of extramedullary hematopoiesis are an extremely rare compensatory process in intermediate and severe thalassemia. Case presentation: We present an unusual case of an intracranial extramedullary hematopoiesis with a choroid plexus origin in a 34-year-old Caucasian man with beta thalassemia intermedia, who presented with the complaints of chronic headache and rapid progressive visual loss. Conclusion: An intracranial extramedullary hematopoiesis, although extremely rare, should be considered as a potential ancillary diagnosis in any thalassemic patient and therefore appropriate studies should be performed to investigate the probable intracranial ectopic marrow before any surgical intervention.
- 19 December 2011
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 5 (1) , 580
Open AccessAn intracranial extramedullary hematopoiesis in a 34-year-old man with beta thalassemia: a case report
Introduction: Extramedullary hematopoiesis occurs in approximately 15% of cases of thalassemia. Intracranial deposits of extramedullary hematopoiesis are an extremely rare compensatory process in intermediate and severe thalassemia. Case presentation: We present an unusual case of an intracranial extramedullary hematopoiesis with a choroid plexus origin in a 34-year-old Caucasian man with beta thalassemia intermedia, who presented with the complaints of chronic headache and rapid progressive visual loss. Conclusion: An intracranial extramedullary hematopoiesis, although extremely rare, should be considered as a potential ancillary diagnosis in any thalassemic patient and therefore appropriate studies should be performed to investigate the probable intracranial ectopic marrow before any surgical intervention.